Global Genomics Group (G3) has entered into a research collaboration with Sanofi to identify new signaling pathways and targets involved in coronary artery disease. G3 will receive undisclosed payments from Sanofi under the collaboration.  

The companies will use G3’s platform with data from its G³LOBAL Database to further decipher the molecular underpinnings of LDL-cholesterol regulation and to better understand which patients may benefit from interference with these signaling pathways.

“Our G³LOBAL Database has been developed as a tool that enables drug developers and biomedical research scientists to better understand molecular networks that underlie human disease and thus improve the drug discovery and development process,” said Szilard Voros, M.D., founder and chief executive officer of G3. “We believe that precision phenotyping, pan-omics and systems-biology driven bioinformatics are the key components of target identification, validation and the elucidation of novel pathways.”